Despite this combination raising the levels of anti-apoptotic Bcl-2, it downregulated expression of c-Myc and hTERT, showing ZME as a potential adjuvant for treatment of pre-B-acute lymphoblastic leukemia [198]. This evidence concerns the gene BCL2 and acute lymphoblastic leukemia.